+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Role of tolcapone in the treatment of Parkinson's disease



Role of tolcapone in the treatment of Parkinson's disease



Expert Review of Neurotherapeutics 7(12): 1649-1657



For decades, the cornerstone of treatment for Parkinson's disease (PD) has been levodopa, which provides a smooth clinical response early in the course of disease. However, many PD patients develop motor complications on long-term levodopa therapy. Catechol-O-methyltransferase (COMT) is a selective and widely distributed enzyme involved in the catabolism of levodopa. Tolcapone and entacapone are selective and potent COMT inhibitors that slow the metabolism of levodopa, thus prolonging its effects. While both drugs act peripherally, tolcapone also inhibits COMT in the CNS. Tolcapone has been shown to be an effective adjunct in the treatment of PD in Phase II and III clinical trials, improving motor fluctuations and reducing levodopa requirements. Rare reports of severe hepatotoxicity, however, limited tolcapone's implementation in the treatment of PD. A reappraisal of the data for tolcapone treatment in PD has found that this risk is very small if proper hepatic monitoring guidelines are followed. This article reviews the pharmacology and clinical data on tolcapone, with particular focus on drug safety and the future role of tolcapone therapy in the treatment of PD.

(PDF emailed within 0-6 h: $19.90)

Accession: 055614927

Download citation: RISBibTeXText

PMID: 18052761

DOI: 10.1586/14737175.7.12.1649


Related references

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology 49(3): 665-671, 1997

Tolcapone, bromocriptine, and Parkinson's disease. French Tolcapone Study Group. Lancet 350(9079): 712-713, 1997

A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group. Movement Disorders 13(4): 643-647, 1998

Tolcapone treatment of late stages of Parkinson's disease. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 105(6): 31-34, 2005

Cognitive improvement during Tolcapone treatment in Parkinson's disease. Journal of Neural Transmission 104(8-9): 887-894, 1997

Tolcapone: COMT inhibition for the treatment of Parkinson's disease. Neurology 50(5 Suppl 5): S1-S2, 1998

Treatment of Parkinson's disease with COMT inhibitors: tolcapone. Neurologia 13 Suppl 1: 66-71, 1998

Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone. Movement Disorders 15(3): 497-502, 2000

Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II). Movement Disorders 12(6): 928-934, 1997

Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Pharmacotherapy 19(1): 6-20, 1999

Tolcapone: a different, effective approach to improving dopaminergic treatment in Parkinson's disease. Neurologia 13(2): 74-82, 1998

Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry 78(9): 944-948, 2006

Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment. Neurology 50(5 SUPPL 5): S39-S45, 1998

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 48(1): 81-87, 1997

Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease. Journal of Neural Transmission 110(8): 911-922, 2003